Insud Pharma
10
1
3
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
10.0%
1 terminated/withdrawn out of 10 trials
83.3%
-3.2% vs industry average
70%
7 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage
Role: lead
Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
Role: lead
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
Role: lead
Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females
Role: lead
Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness
Role: lead
A Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, and Tolerability of LPRI-424, 13 Cycles
Role: lead
Safety and Tolerability of Metronidazole Gel 1.3%
Role: lead
Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
Role: lead
Benznidazole Absorption, Metabolism and Excretion Study
Role: collaborator
Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)
Role: lead
All 10 trials loaded